Instead of investigating the potential interplay between the GR and the AR signals in bladder cancer cells, the effects of a unique steroid hormone receptor modulator, compound A [CpdA; 2-(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride] known to function as not only a GR ligand [63] but also an AR antagonist [64], on their growth have been assessed [44]. The gene discussed is NR3C1; the disease is urinary bladder cancer.